Adial Pharmaceuticals, Inc.

NasdaqCM ADIL

Adial Pharmaceuticals, Inc. Price to Book Ratio (P/B) on January 14, 2025

Adial Pharmaceuticals, Inc. Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Adial Pharmaceuticals, Inc. 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Adial Pharmaceuticals, Inc. 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
Adial Pharmaceuticals, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: ADIL

Adial Pharmaceuticals, Inc.

CEO	Mr. Cary John Claiborne MBA
IPO Date	July 27, 2018
Location	United States
Headquarters	1180 Seminole Trail
Employees	4
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Key trends

Past 5 years